Hepatitis B research updates: how to judge news about new drugs, cure, and clinical trials

Viral control, functional cure, and complete clearance are different

Chronic hepatitis B already has treatments that can suppress viral replication and reduce liver injury risk, but many people need long-term therapy. In research news, functional cure usually means sustained HBsAg loss after a finite treatment course with undetectable HBV DNA; whether anti-HBs must appear can differ by definition. It does not mean every trace of virus has been removed from every cell.

When you see a cure headline, look beyond the title. Ask who was studied, how many people participated, which trial phase it was, how long follow-up lasted, whether nucleos(t)ide analogue treatment continued, how many serious adverse events occurred, and whether results are published in peer-reviewed literature or regulatory documents.

Drug Watch helps identify the development stage

Hepatitis B Foundation Drug Watch lists approved medicines and investigational chronic hepatitis B drugs. Use it to ask three questions: Is this drug approved or still being studied? What is the mechanism? Is it preclinical, phase 1, phase 2, or phase 3?

Earlier stages are usually farther from routine clinical use. Phase 1 focuses more on safety and dose. Phase 2 looks for efficacy signals. Phase 3 is closer to confirming benefit and safety. Even positive phase 3 data may still require regulatory review, indication limits, price decisions, and access planning.

Clinical trials are not simply early access to a new drug

ClinicalTrials.gov and Hepatitis B Foundation trial tools can help locate hepatitis B, hepatitis D, and liver cancer studies. Each trial has eligibility criteria, exclusion criteria, location, status, and contacts. Criteria may include age, HBV DNA, HBsAg level, HBeAg status, prior treatment, cirrhosis, coinfections, pregnancy plans, and kidney function.

Before joining, confirm ethical review, potential benefits and risks, whether current medicines must stop or change, who pays for tests and travel, and how treatment continues after withdrawal or trial completion. Do not stop antivirals to qualify for a trial, and do not pay unclear enrollment fees to unknown organizations.

What research progress means for you now

Keep doing what is already known to help: attend monitoring visits, assess treatment need, vaccinate susceptible family members, avoid alcohol, and avoid unnecessary liver-toxic risks. Save key results such as quantitative HBsAg, HBV DNA, ALT/AST, HBeAg/anti-HBe, fibrosis assessment, and ultrasound. These results may matter for future trial eligibility and current treatment decisions.

Action checklist

Turn each news story into four questions: Which patients were studied? What endpoint was used? What were the safety findings? When, where, and for whom could it become available? If the answers are unclear, treat it as research to watch, not a reason to change treatment. Bring promising trial or drug names to your clinician and ask whether they are relevant to your stage, cirrhosis risk, and other conditions.